Anodyne

Enable Hints
Enable jsmol
Collapse all
Toggle theme
2C-B
Generated by the Chemistry Development Kit (http://github.com/cdk)
Salts
[]
2,5-Dimethoxy-4-bromophenethylamine hydrochloride
Generated by the Chemistry Development Kit (http://github.com/cdk)
2,5-Dimethoxy-4-bromophenethylamine hydrobromide
Generated by the Chemistry Development Kit (http://github.com/cdk)
Molecular structure via molpic based on CDK
Physical properties
[]
260.13 g/mol [1]
2.1 [1]
Structural Identifiers
[]
C10H14BrNO2 [1]
2-(4-bromo-2,5-dimethoxyphenyl)ethanamine [1]
COC1=CC(=C(C=C1CCN)OC)Br [1]
InChI=1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3 [1]
InChIKeyYMHOBZXQZVXHBM-UHFFFAOYSA-N [1]
Pharmacokinetics[]
Elimination half-life1.2 – 2.5 hours[3][4]
Duration of actionOral: 2 – 8 hours[5]
Dosing[]
Insufflated
[]
Light≤ 8.3 mg(21x - 36.2%)
Common8.3 - 10 mg(20x - 34.5%)
Strong10 - 13.8 mg(2x - 3.4%)
Heavy13.8 - 17.3 mg(9x - 15.5%)
Extreme17.3 mg +(6x - 10.3%)
Oral
[]
Light≤ 17 mg(4x - 28.6%)
Common17 - 21 mg(3x - 21.4%)
Strong21 - 25 mg(4x - 28.6%)
Heavy25 - 34.4 mg(1x - 7.1%)
Extreme34.4 mg +(2x - 14.3%)
Intrarectal
[]
Light≤ 12.4 mg(6x - 50%)
Common12.4 - 13.5 mg
Strong13.5 - 20 mg(4x - 33.3%)
Heavy20 - 24 mg
Extreme24 mg +(2x - 16.7%)
Statistically derived dosages via DBI-IGS
We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

2,5-Dimethoxy-4-bromophenethylamine

2,5-Dimethoxy-4-bromophenethylamine (also known as 4-Bromo-2,5-dimethoxyphenethylamine, 2-(4-Bromo-2,5-dimethoxyphenyl)ethylamine, 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine, 4-Bromo-2,5-dimethoxyphenylethylamine, Benzeneethanamine, 4-bromo-2,5-dimethoxy-, 2C-B, Nexus, BDMPEA, 2-CB or 4-Bromo-2,5-dimethoxybenzeneethanamine) is a psychedelic substance of the 2,5-dimethoxyphenethylamine class.

Chemistry

Salts []

2,5-Dimethoxy-4-bromophenethylamine is typically found in the form of its hydrochloride and hydrobromide salts.

 []

2,5-Dimethoxy-4-bromophenethylamine is a achiral mixture

Anodyne Usernotes
[]
magnus / 2,5-Dimethoxy-4-bromophenethylamine at 22-44mg oral, 22mg insufflated and 11-66mg intrarectal
  • lovechild of lsd and mdma; ; ; prettiest visuals I‘ve ever had on 66mg boofed in combination with 4mg of Clonazepam; slight when boofed
0xea / 2,5-Dimethoxy-4-bromophenethylamine via map[Name:Oral] and Intravenous

Legal status []

  • Australia: 2,5-Dimethoxy-4-bromophenethylamine is a Schedule 9 substance.
  • Brazil: 2,5-Dimethoxy-4-bromophenethylamine is a F2 substance.
  • Canada: 2,5-Dimethoxy-4-bromophenethylamine is a Schedule III substance.
  • Germany: 2,5-Dimethoxy-4-bromophenethylamine is a Anlage I substance.
  • United Kingdom: 2,5-Dimethoxy-4-bromophenethylamine is a Class A substance.
  • United States: 2,5-Dimethoxy-4-bromophenethylamine is a Schedule I under the "Controlled Substances Act (CSA)".
  • United Nations: 2,5-Dimethoxy-4-bromophenethylamine is a Schedule II drug under the "Convention on Psychotropic Substances 1971".

See also []

  • 4-Substituted 2,5-dimethoxyphenethylamines (2C-x)
  • Anodyne

    • External links []

    References []

    1. National Center for Biotechnology Information. PubChem Compound Summary for CID 98527, 2,5-Dimethoxy-4-bromophenethylamine. Accessed October 14, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/98527

    2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. 2,5-Dimethoxy-4-bromophenethylamine. UNII: V77772N32H. Global Substance Registration System. Accessed October 14, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/V77772N32H

    3. Papaseit E, Farré M, Pérez-Mañá C, Torrens M, Ventura M, Pujadas M, de la Torre R, González D. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. Frontiers in Pharmacology. 2018; 9

    4. Thomann J, Rudin D, Kraus S, Arikci D, Holze F, Liechti ME, Luethi D. LC–MS/MS-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolites in human plasma. Drug Metabolism and Disposition. 2025; 53(6)

    5. Inan F, Brunt TM, Contrucci RR, Hondebrink L, Franssen EJ. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. Ther Drug Monit. April 1, 2020; 42(2):271–281.